Atezolizumab, a selective, high-affinity monoclonal antibody to human IgG, specifically block the binding of PD-L1 to PD-1, restoring the immune surveillance function of T cells, which in turn helps T cells recognize and kill tumor cells, and has been used as a first-line treatment for advanced HCC [3, 7]. The gene discussed is CD274; the disease is neoplasm.